[103a] HYPE VS. HOPE: USING AI TO DETECT DISEASE

Yaron Gurovich, CTO, FDNA

- **Investment Rational**
  FDNA develops AI technologies and SaaS platforms used by thousands of clinical, research, and lab sites globally in the clinical genomics space. FDNA's database includes an unprecedented depth of phenotypic and genotypic information associated with more than 10,000 diseases, crowdsourced from real-world patient cases through out broad network of users.

- **Business Strategy**
  FDNA's flagship technology, Face2Gene, is a suite of phenotyping applications used by 70% of the world's geneticists across 2,000 clinical sites in 130 countries. FDNA is currently working with select partners to license an embedded version of the technology to be integrated into third party platforms.

- **Core Technology**
  Using advanced deep learning, FDNA's next-generation phenotyping (NGP) technologies capture, structure, and analyze complex human physiological data to produce actionable insights. The technology, called DeepGestalt, was recently featured in Nature Medicine, and recent studies show that when NGP technologies are combined with next-generation sequencing (NGS) analysis tools, the diagnostic yield increases to 98% with top-10 accuracy.

- **Product Profile/Pipeline**
  Continuing to refine and update features of flagship product, Face2Gene, while also developing an embedded version of the technology for commercialization.

- **What's Next?**
  R&D – embedded version of the technology; expand to look at other biomarkers beyond the face.
  Preclinical / Clinicals – partnering with organizations for clinical trial recruitment
  Organizational plans – expanding the company across all departments
  Financial plans – commercialize technology, license embedded version